Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr. Chase on Future Treatment Landscape of Gynecologic Malignancies

August 10th 2017

Dana M. Chase, MD, FACOG, an associate professor at Creighton University, University of Arizona College of Medicine, and gynecologic oncologist with Arizona Oncology, discusses the future treatment landscape of gynecologic malignancies, including vulvar cancer, endometrial cancer, and cervical cancer.

Dr. Arend Discusses MSI Testing in Gynecologic Malignancies

August 10th 2017

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses microsatellite instability testing in patients with gynecologic malignancies.

Bevacizumab OS Benefit Confirmed in Cervical Cancer

August 9th 2017

Adding bevacizumab (Avastin) to chemotherapy improved overall survival for women with cervical cancer, according to final results from the phase III GOG 240 trial.

Dr. Arend Discusses Targets in Endometrial Cancer

August 2nd 2017

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses targeted therapies in endometrial cancer.

Adjuvant Chemotherapy Reduces Distant Recurrence Risk in Cervical Cancer

July 24th 2017

Systemic chemotherapy administered post-surgery reduced the risk for distant recurrence in women with node-positive stage IB-IIB cervical cancer.

Expert Discusses Pathology for Ovarian and Endometrial Cancer

July 20th 2017

Douglas A. Levine, MD, discusses the role of pathology in endometrial and ovarian cancer, and highlights when a patient should be tested for BRCA mutations.

Nivolumab Active in Advanced Gynecologic Cancers

July 20th 2017

Nivolumab demonstrated clinical activity in women with recurrent/metastatic cervical cancer, and was active to a lesser extent in vaginal and vulvar cancers.

ODAC Unanimously Supports Bevacizumab Biosimilar ABP-215

July 13th 2017

The FDA’s Oncologic Drugs Advisory Committee voted 17-0 to recommend approval for ABP-215, a biosimilar for bevacizumab (Avastin) to treat a range of solid tumors.

Dr. Arend on the PORTEC-3 Trial for Endometrial Cancer

July 7th 2017

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the PORTEC-3 trial for patients with endometrial cancer.

Expert Discusses Recent Endometrial Cancer Research

June 23rd 2017

Rebecca C. Arend, MD, discusses highlights from the ASCO meeting and other key developments in endometrial cancer.

Dr. Birrer on Checkpoint Inhibitors for Endometrial Cancer

June 20th 2017

Michael Birrer, MD, PhD, UAB Comprehensive Cancer Center in Alabama, discusses checkpoint inhibitors for patients with endometrial cancer.

Lurbinectedin Shows Promise in Endometrial Cancer

June 18th 2017

Lurbinectedin (PM01183) induced a high rate of response as monotherapy and with doxorubicin or paclitaxel in patients with advanced endometrial cancer.

Dr. Leath on Ongoing Trials for Endometrial Cancer

June 9th 2017

Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses ongoing trials for patients with endometrial cancer.

Dr. Arend on Personalized Medicine for Endometrial Cancer

June 9th 2017

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses personalized medicine for patients with endometrial cancer.

Pembrolizumab Demonstrates Durable Response in PD-L1+ Endometrial Cancer

May 30th 2017

Results from the KEYNOTE-028 study showed that pembrolizumab (Keytruda) was associated with a median duration of response of 6 months and a 6-month progression-free survival rate of 40.4% in women with advanced PD-L1–positive endometrial cancer.

Dr. Wingo on Advances of Surgical Technology in Gynecologic Cancers

May 25th 2017

Shana Wingo, MD, gynecologic oncology, Arizona Oncology, discusses the advances of surgical technology in gynecologic cancers.

Dr. Chase Discusses Risk Factors in Gynecologic Cancers

May 23rd 2017

Dana M. Chase, MD, FACOG, an associate professor at Creighton University, University of Arizona College of Medicine, and gynecologist oncologist with Arizona Oncology, discusses the risk factors in gynecologic cancers.

Study Warns Women of Premature Discontinuation of Cervical Cancer Screening

May 16th 2017

Mary C. White, ScD, MPH, discusses the unmet needs near and after the stopping age for cervical cancer screening.

Dr. Beddoe on the Impact of Cervical Cancer Screening

May 11th 2017

Ann Marie Beddoe, MD, assistant professor of Obstetrics, Gynecology and Reproductive Science, Mount Sinai Hospital, discusses the impact of cervical cancer screening for women in the United States.

Zoptarelin Doxorubicin Falls Short in Phase III Endometrial Cancer Trial

May 5th 2017

Zoptarelin doxorubicin (Zoptrex), a hybrid molecule combining an LHRH-agonist and doxorubicin, failed to improve median overall survival in a phase III advanced endometrial cancer trial, according to the manufacturer of the treatment, Aeterna Zentaris.